Literature DB >> 32323276

B Cell Lymphoma.

Xin Meng1, Qing Min1, Ji-Yang Wang2.   

Abstract

B cell development and activation are accompanied by dynamic genetic alterations including V(D)J rearrangements and immunoglobulin-gene somatic hypermutation and class-switch recombination. Abnormalities in these genetic events can cause chromosomal translocations and genomic mutations, leading to altered expression and function of genes involved in B cell survival or proliferation and consequently B lymphomagenesis. In fact, B cell lymphoma accounts for 95% of the lymphomas. In this chapter, we summarize the morphology, immunophenotypes, clinical features, genetic defects that cause the malignancies, treatments, and prognosis of the most prevalent types of B cell lymphomas, including typical precursor B cell malignance (B-ALL/LBL) and mature B cell lymphoma (Hodgkin lymphoma and B cell non-Hodgkin lymphoma).

Entities:  

Keywords:  B cell non-Hodgkin lymphoma; B lymphoblastic leukemia/lymphoma; Chromosomal translocation; Hodgkin lymphoma; Molecular target therapy

Mesh:

Year:  2020        PMID: 32323276     DOI: 10.1007/978-981-15-3532-1_12

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  4 in total

1.  Long-term efficacy of CAR-T cell therapy for patients with relapsed/refractory B cell non-Hodgkin lymphoma.

Authors:  Shan Fu; Yongxian Hu; He Huang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2022-04-25

2.  SEPT6_TRIM33 Gene Fusion and Mutated TP53 Pathway Associate With Unfavorable Prognosis in Patients With B-Cell Lymphomas.

Authors:  Haiying Fu; Huarong Zhou; Yanyan Qiu; Jianfei Wang; Zhiming Ma; Hongping Li; Feng Zhang; Chenxi Qiu; Jianzhen Shen; Tingbo Liu
Journal:  Front Oncol       Date:  2021-12-01       Impact factor: 6.244

Review 3.  PET/CT Evaluation of the Effect of Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of T-Cell Lymphoblastic Lymphoma.

Authors:  Jin Zhao; Xiaojing Guo; Li Ma; Meijing Zheng; Tao Guan; Liping Su
Journal:  Contrast Media Mol Imaging       Date:  2022-08-16       Impact factor: 3.009

4.  Silencing Aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing β-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway.

Authors:  Shaoxiong Wang; Li Sun
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.